^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AZD5069

i
Other names: AZD5069
Associations
Trials
Company:
AstraZeneca
Drug class:
CXCR2 antagonist
Associations
Trials
6ms
Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro. (PubMed, J Endocrinol Invest)
Our findings confirm the involvement of the CXCL8/CXCR2-axis in promoting pro-tumorigenic effects in TC cells, further demonstrating its immunotherapeutic significance in human cancer.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
AZD5069
6ms
A microphysiological system reveals neutrophil contact-dependent attenuation of pancreatic tumor progression by CXCR2 inhibition-based immunotherapy. (PubMed, Sci Rep)
Interestingly, treatment with AZD-5069, a CXCR2 inhibitor, attenuates invasion and proliferation of tumor spheroids by blocking direct contact with neutrophils. Our findings also show that CXCR2 inhibition reduces neutrophil migration toward tumor spheroids. These results shed new light on the tumor-promoting mechanisms of human neutrophils and the tumor-suppressive mechanisms of CXCR2 inhibition in pancreatic cancer and may aid in the design and optimization of novel immunotherapeutic strategies based on neutrophils.
Journal
|
CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
AZD5069
7ms
Cell-specific nanoengineering strategy disrupts tolerogenic signaling from myeloid-derived suppressor cells to invigorate antitumor immunity in pancreatic cancer. (PubMed, bioRxiv)
We conjugate a chemically modified small-molecule inhibitor of MDSC-surface receptor CXCR2 (AZD5069) with polyethylene glycol (PEG) and chemically graft AZD5069-PEG constructs onto amphiphilic polysaccharide derivatives to engineer CXCR2-homing nanoparticles (CXCR2-NP). Encapsulation of JAK2/STAT3i Ruxolitinib (CXCR2-NP Ruxo ) resulted in more durable attenuation in STAT3-regulated arginase activity from PMN-MDSCs and induction of cytolytic T-cell activity vs. free Ruxolitinib in-vitro and in-vivo . Cell-specific delivery of payloads via CXCR2-homing immunonanoparticles represents a novel strategy to disrupt MDSC-mediated immunosuppression and invigorate antitumor immunity in PDAC.
Journal
|
JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
Jakafi (ruxolitinib) • AZD5069
12ms
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov)
P1/2, N=340, Active, not recruiting, AstraZeneca | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2023 --> Mar 2025
Phase classification • Trial completion date • Combination therapy • Metastases
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • AZD5069 • danvatirsen (AZD9150)
over1year
Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression. (PubMed, Gastric Cancer)
Our findings reveal that blocking GCMSCs-derived IL-8/CXCR2 pathway decreasing PD-L1 expression and lactate production, improving antitumor efficacy of anti-PD-1 immunotherapy, may be of value for the treatment of advanced gastric carcinoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
PD-L1 expression • CXCL8 expression
|
AZD5069
over1year
Combination Study of AZD5069 and Enzalutamide. (clinicaltrials.gov)
P1/2, N=30, Terminated, Institute of Cancer Research, United Kingdom | N=86 --> 30 | Trial completion date: Oct 2023 --> Nov 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2023 --> Sep 2022; Discontinuation of production of IMP
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
Xtandi (enzalutamide) • AZD5069
over1year
REDUCED EXPRESSION OF THE CHEMOKINES CXCL2, CXCL3 AND CXCL8 PROVIDES A POTENTIAL MECHANISM PROMOTING IMMUNE EVASION FACILITATING AML RELAPSE FOLLOWING ALLOGENEIC HSCT (EHA 2023)
Conversely, CXCR2 inhibition with AZD5069 led to reduced CD4 proliferation and PD-1 expression.Summary/ This study further highlights the importance of immune evasion in mediating AML relapse following AHSCT. This study further highlights the importance of immune evasion in mediating AML relapse following AHSCT. The chemokines CXCL2 and CXCL8 were identified as potential mediators of this process and may provide prospective targets to enhance the GvL effect to prevent or treat post-AHSCT relapse. Diagram Description automatically generated Chemokine, Acute myeloid leukemia, Allogeneic hematopoietic stem cell transplant
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD4 (CD4 Molecule) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
|
PD-1 expression • CXCL8 expression
|
AZD5069
over1year
Myeloid IL-8 enrichment associates with immunotherapy resistance in advanced hepatocellular carcinoma (EASL-ILC 2023)
In this study, we analyzed the immune contexture of advanced HCC patients before and after pembrolizumab treatment to investigate the role of myeloid IL-8 in ICB-resistance mechanism and aim to intervene the IL-8 pathway through inhibition of its receptor by a clinical in-use CXCR2 antagonist...Therapeutic efficacy of CXCR2 pathway inhibition by AZD5069 in potentiating ICB response was evaluated in our ICB-resistant orthotopic mouse model which is generated by serial in vivo passaging of anti-PD-L1 residual tumor... We demonstrated the importance of myeloid IL-8/CXCR2 pathway in ICB-resistance from our advanced HCC cohort which paved way for IL-8 to become a novel prognostic target for immunotherapy. Blocking CXCR2 could reduce MDSC trafficking and overcome ICB-resistance in our pre-clinical HCC model, suggesting a promising combination regimen in future development.
PD(L)-1 Biomarker • IO biomarker • Metastases
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
CXCL8 expression
|
Keytruda (pembrolizumab) • AZD5069
2years
A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC). (ASCO-GI 2023)
The 2nd dose cohort opened to recruitment in September 2022. Exploratory studies (blood; pre- & on-treatment tumor and non-malignant liver biopsies) include biomarkers of CXCR2 inhibition (blood); proof-of-mechanism (tumor: expression of CXCR2, PD-L1, PD-1, CD8, CD4, CD66b, CD69); proof-of-mechanism (blood: ctDNA); drug-induced changes of mRNA expression, CXCR2 ligands & signalling pathway genes, T-cell and myeloid cell pathways, neutrophil-associated genes; predictive biomarkers (blood and tumour) include biomarkers of the CXCR2/PD-L1 immune axis; aberrant CXCR2 signalling pathways; proliferation biomarkers and CD10 (neutrophils), CD68 (macrophages), CD103 (T-regs); tumour mutational status.
Clinical • P1/2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • CD68 (CD68 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CEACAM8 (CEA Cell Adhesion Molecule 8)
|
PD-L1 expression
|
Imfinzi (durvalumab) • AZD5069
2years
Trial completion date • Combination therapy • IO biomarker • Metastases
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
PD-L1 expression
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • AZD5069 • danvatirsen (AZD9150)
over2years
CXCR2-targeting nanoparticles to abrogate tolerogenic signaling in myeloid-derived suppressor cells in pancreatic cancer | Poster Board #2712 (ACS-Fall 2022)
We then chemically modified a surface receptor inhibitor of CXCR2 AZD5069 by conjugating it with polyethylene glycol to enhance aqueous solubility. Finally, co-culture of splenocyte-derived murine CD8+ T-cells with J774 treated with Ruxolitinib-NPCXCR2 showed significant improvement in T-cell IFN-γ release compared with free Ruxolitinib. Compartment-specific delivery of payloads targeting tolerogenic signaling in gMDSC via NPCXCR2 may represent a novel strategy to mitigate immunosuppression in PDAC.
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
Jakafi (ruxolitinib) • AZD5069
over2years
NOTCH1 driven metastasis in BRAF mutated colorectal cancer (ESMO 2022)
Neutrophils were targeted in BPN mice with AZD5069 (CXCR2 inhibitor) +/- anti-PD1 antibody or vehicle control from 85 days post Cre induction (DPI)...Metastasis is reduced by neutrophil inhibition which synergises with anti PD1 therapy, supporting an actionable phenotype. The NAS identifies a poor prognostic patient group and future work will see if neutrophil targeted therapy could benefit these patients.
PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • NICD (NOTCH1 intracellular domain)
|
BRAF V600E • KRAS mutation • BRAF mutation • BRAF V600 • KRAS G12D • KRAS G12
|
AZD5069
over2years
A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) (ESMO 2022)
Conclusions The combination of AZD5069 and ENZA is tolerable and has antitumor activity in mCRPC. We provide clinical evidence for direct targeting of myeloid chemotaxis as a therapeutic strategy in mCRPC.
Clinical • Combination therapy
|
NRG1 (Neuregulin 1) • IL23A (Interleukin 23 Subunit Alpha) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
Xtandi (enzalutamide) • AZD5069
over2years
CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer. (PubMed, Front Pharmacol)
CXCR2 inhibition abrogated doxorubicin-mediated TGF-β upregulation in 3D in vitro TNBC coculture with PBMCs and eliminated drug resistance in TNBC mammospheres, suggesting a vital role for CXCR2 in TNBC doxorubicin-resistance via TGF-β signaling regulation. Moreover, CXCR2 inhibition improved the efficacy of the immunotherapeutic drug "atezolizumab" where the combined inhibition of CXCR2 and PDL1 in TNBC in vitro coculture showed an additive effect in cytotoxicity. Altogether, the current study suggests CXCR2 inhibitors as a promising approach to improve TNBC treatment if used in combination with chemotherapy and/or immunotherapy.
Journal
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
Tecentriq (atezolizumab) • doxorubicin hydrochloride • AZD5069
almost3years
CXCR2 Mediates Distinct Neutrophil Behavior in Brain Metastatic Breast Tumor. (PubMed, Cancers (Basel))
Inhibition of CXCR2 using small molecule antagonist AZD5069 reversed this behavior, limiting the neutrophil responses to the BrM and retarding the reciprocal tumor development. We further demonstrate that abrogation of NETs formation using Neutrophil Elastase Inhibitor (NEI) significantly decreases the influx of neutrophils towards BrM but not to their parental tumor, suggesting that CXCR2 activation could be used by the brain metastatic tumors as a mechanism to program the tumor-infiltrating TANs into a pro-NETotic state, so as to assume a unique spatial distribution that assists in the subsequent migration and invasion of the metastatic tumor cells. This new perspective indicates that CXCR2 is a critical target for suppressing neutrophilic inflammation in brain metastasis.
Journal
|
CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
AZD5069
almost3years
Investigating CXCR2 inhibition + anti-PD1 immunotherapy in a NASHHCC mouse model using Imaging Mass Cytometry (LCS 2022)
In this study we employ Imaging Mass Cytometry (IMC) to determine how co-therapy of anti-PD1 (Biolegend) and a small molecule inhibitor of the neutrophil chemokine receptor CXCR2 (AZD5069 – AstraZeneca) remodels the tumour microenvironment (TME) in a murine model of NASH-HCC... IMC allows for the identification of multiple cell types in a spatial context and quantification of changes in cell-cell interactions within the TME. In this study, IMC demonstrated that combined antiPD1 and CXCR2 inhibitor therapy in NASH-HCC encouraged the formation of cytotoxic immune hubs containing locally proliferating neutrophils, CD8+ T cells and antigen presenting cells. We then propose that the manipulation of neutrophils may have therapeutic potential in NASH-HCC.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
AZD5069
3years
Trial completion date • Combination therapy • IO biomarker
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
PD-L1 expression
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • AZD5069 • danvatirsen (AZD9150)
almost4years
[VIRTUAL] CXCR2 small molecule antagonists: A novel approach to enhance the effect of PDL-1 inhibitors in triple-negative breast cancer (ESMO-BC 2021)
Here, we investigate the potential use of AZD5069 in combination with atezolizumab (anti-PD-L1) in an ex-vivo TNBC model.   CXCR2 mRNA expression was analyzed using RealTime PCR in 65 BC biopsies and controls.  These data highlight the role of CXCR2 inhibition as a cutting edge approach to boost immunotherapy and combat chemo-resistance in TNBC.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
HER-2 overexpression
|
Tecentriq (atezolizumab) • AZD5069
4years
CXCR2 blockade disrupts tumor trafficking of MDSC to potentiate immunotherapy efficacy (IDDF 2020)
Therapeutic efficacy of CXCR2 blockade was conducted in an orthotopic mouse model using AZD5069 (100 or 150 mg/kg) which is a CXCR2 antagonist currently undergoing clinical trials and in combination with anti-PD-L1 antibody (10F.9G2)...Conclusions Our data demonstrated the intricate link between IL-8/CXCR2 axis and MDSC trafficking to TME, providing insight into the immunosuppression mechanism in HCC. Targeting IL-8/CXCR2 chemotaxis pathway may potentiate ICB responsiveness, serving as a novel potential therapeutic option for effectively combined immunotherapy in liver cancer.
Clinical
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
CXCL8 elevation • CXCL8 expression
|
AZD5069
over4years
Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. (PubMed, NAR Cancer)
In vivo, administration of a CXCR1/2-targeted pepducin (x1/2pal-i3), or CXCR2-specific antagonist (AZD5069), in combination with IR to PTEN-deficient xenografts attenuated tumour growth and progression compared to control or IR alone. Post-mortem analysis confirmed that x1/2pal-i3 administration attenuated IR-induced CXCL signalling and anti-apoptotic protein expression. Interventions targeting CXC chemokine signalling may provide an effective strategy to combine with RT in locally advanced prostate cancer patients with known presence of PTEN-deficient foci.
Clinical • Journal
|
PTEN (Phosphatase and tensin homolog) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
AZD5069